Actively Recruiting
Phase II Study of Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and ABO-Incompatible Matched Sibling Donor
Led by University of Calgary · Updated on 2026-05-01
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new nonmyeloablative conditioning regimen for hematopoietic stem cell transplantation HSCT in children with sickle cell disease SCD who have a matched related donor with a major ABO blood group incompatibility. This phase II pilot study aims to assess the safety and effectiveness of this regimen, which includes alemtuzumab, total body irradiation, and sirolimus for immune suppression, to expand HSCT access for SCD patients who are currently ineligible due to donor restrictions. The study also focuses on monitoring red blood cell engraftment and preventing pure red cell aplasia PRCA, a potential complication in this setting. The treatment involves a nonmyeloablative conditioning approach consisting of alemtuzumab administered subcutaneously once daily for five days before transplant, a single dose of 300 cGy total body irradiation two days before transplant, and sirolimus for graft-versus-host disease GVHD prevention. The study includes biological monitoring to detect early signs of complications and to evaluate engraftment success. This regimen is being studied specifically in pediatric patients with matched related donors who have major ABO incompatibility. Participants will be closely followed for various outcomes including the incidence of PRCA within six months, graft failure, disease recurrence, and acute or chronic GVHD over periods ranging from 100 days to 24 months. Assessments include blood tests to measure red blood cell chimerism in peripheral blood and bone marrow, as well as clinical evaluations of transplant success and complications. The total participation duration may extend up to two years to monitor long-term outcomes and safety.
CONDITIONS
Brief Title
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Research Team
T
Tony Truong, MD, MPH
G
Greg Guilcher, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here